FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Federal Register

FDA Delays Review Action on Alzheimers Drug

FDA delays by three months its decision on Eisai and Biogen's subcutaneous starting-dose formulation of Alzheimers drug Leqembi (lecanemab) after the ...

latest-news-card-1
FDA General

Legal Analysis Highlights Impact of FDA AI Clinical Trial Pilot

A legal analysis published by Crowell & Moring says a proposed FDA pilot program on artificial intelligence in early-stage clinical trials could shape...

latest-news-card-1
FDA General

Trump Denies Makary is on the Outs

President Trump tells reporters he knows nothing about reports suggesting FDA commissioner Marty Makary will be asked to resign soon.

latest-news-card-1
Human Drugs

Guide on Submitting Continuous Glucose Monitoring Data

FDA posts new technical guidance document outlining how sponsors should submit continuous glucose monitoring data collected during clinical trials for...

latest-news-card-1
Medical Devices

Boston Scientific Device Correction on Certain Pacemakers

Boston Scientific begins a Class 1 recall (device correction) involving certain pacemakers and cardiac resynchronization therapy pacemakers following ...

latest-news-card-1
Animal Drugs

White House Reportedly Moves to Oust Commissioner Makary

Several media outlets report that President Trump has signed off on a plan to remove FDA commissioner Marty Makary from his post.

latest-news-card-1
Biologics

Partner Therapeutics Wins Approval for Bile Duct Cancer Therapy

FDA approves a Partner Therapeutics BLA for Bizengri (zenocutuzumab-zbco) for adults with advanced, unresectable or metastatic cholangiocarcinoma harb...

latest-news-card-1
Animal Drugs

Atara says FDA outlined potential path for Cell Therapy Resubmission

Atara Biotherapeutics says it and partner Pierre Fabre Pharmaceuticals have received feedback from FDA outlining a potential path toward resubmitting ...

latest-news-card-1
Human Drugs

Postapproval Pregnancy Safety Studies Guidance Available

FDA releases a new guidance outlining how drugmakers should design and conduct postapproval studies evaluating the safety of drugs and biologics used ...

latest-news-card-1
Human Drugs

New CDER Biologics Compliance Program Explained

Two Alston & Bird attorneys give a comprehensive analysis of the new CDER compliance program for pre-license and preapproval inspections of CDER-regul...